NovoCure Limited (NVCR) stock analysis
Healthcare · Medical Devices
From the 10-K filed 2026-02-26
How it makes money
It bills patients and payers monthly for therapy usage, with revenue driven by monthly fees, duration of treatment, and reimbursement success.
It charges for treatment with its therapy devices on a monthly basis across multiple active markets. Potential net revenues per patient depend directly on its ability to secure payment, the monthly fee collected, and the number of months that the patient remains on therapy. Most of its revenues come from the use of its primary device in the U.S., Germany, France, and Japan.
What protects it: the moat
It relies on an extensive portfolio of hundreds of issued patents and pending applications worldwide to protect its proprietary technology.
Management asserts that its intellectual property portfolio contains hundreds of issued patents and numerous patent applications pending worldwide. It also relies on regulatory pathways such as Premarket Approval and Humanitarian Device Exemption to market its medical devices for specific cancer indications.
What growth costs
It continuously reinvests in research, development, clinical studies, and commercial sales and marketing to expand indications and drive adoption.
Operating expenses consist of research, development and clinical studies, sales and marketing, and general and administrative expenses. Research and development expenses include personnel costs, third-party clinical study contracts, and manufacturing expenses for devices utilized in clinical research. Sales and marketing expenses cover personnel costs, travel, promotional activities, medical education, market access, and commercial shipping.
What could damage it
If it fails to secure and maintain adequate coverage or reimbursement from third-party payers, its revenues and commercial success will be severely harmed.
Its business depends heavily on its ability to obtain and maintain sufficient coverage or reimbursement by private and governmental third-party payers. Without widespread reimbursement agreements, especially for newly approved indications, patient access is restricted, directly reducing the sales and royalties required to sustain operations.
About NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.